In this Healio Video Perspective from the Tear Film & Ocular Surface Society meeting, Melissa Toyos, MD, FACS, discusses positive pharmacovigilance data for Lumify for the treatment of ocular redness.
Lumify (brimonidine tartrate ophthalmic solution 0.025%, Bausch + Lomb), an alpha-2 adrenergic receptor agonist, had a low number of adverse events, and rebound redness was low compared with other available products. These results can be attributed to Lumify’s mechanism of action as a vasoconstrictor, according to Toyos.
“When we are constricting the veins, we actually get better